Xenon names Matthew Ronsheim as chief operating officer

Xenon Pharmaceuticals ( NASDAQ: XENE ) on Monday announced the appointment of Matthew Ronsheim as chief operating officer. Ronsheim has 25 years of experience bringing important medicines from discovery through clinical development, global regulatory filings and approvals, and commercial launch and supply. Prior to Xenon, Ronsheim was president of Innoviva Specialty Therapeutics, having served as chief technical officer.

Press release. More on Xenon Pharma Xenon Pharmaceuticals: Good Data In Epilepsy, But Doubts Remain Xenon Pharmaceuticals, Inc. (XENE) Q2 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Xenon Pharma Historical earnings data for Xenon Pharma Financial information for Xenon Pharma.